New Immunotherapy for Multiple Myeloma
The FDA granted accelerated approval to a targeted immunotherapy for patients with relapsed or refractory multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to teclistamab-cqyv (Tecvayli), a type of...
